Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. Comments on Unusual Trading Activity
Oct 28, 2013
PDF 109.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Sep 25, 2013
PDF 107.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Pre-Clinical Poster Presentation for TGR-1202 at the 15th International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Cologne, Germany
Sep 9, 2013
PDF 147.2 KB Add to Briefcase
View Summary TG Therapeutics' Ublituximab (TG-1101) Receives Orphan Drug Designation for the Treatment of Nodal Marginal Zone Lymphoma and Extranodal Marginal Zone Lymphoma (Mucosa-Associated Lymphatic Tissue, MALT)
Sep 9, 2013
PDF 110.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Second Quarter 2013 Financial Results and Business Update
Aug 1, 2013
PDF 118.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2013 Financial Results and Business Update
Jul 31, 2013
PDF 107.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Exercise of Option to Purchase Additional Shares
Jul 26, 2013
PDF 110.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Jul 18, 2013
PDF 110.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Jul 17, 2013
PDF 108.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 8th Annual JMP Securities Healthcare Conference
Jul 8, 2013
PDF 107.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Presentation of Pre-Clinical Data on the Combination of TG-1101 and TGR-1202 at the International Conference on Malignant Lymphoma, Lugano, Switzerland
Jun 19, 2013
PDF 110.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical and Pre-Clinical Poster Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Stockholm, Sweden
Jun 17, 2013
PDF 136.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase I/II Clinical Trial of Single-Agent Ublituximab (TG-1101) in Patients With Rituximab Relapsed/Refractory Non-Hodgkin's Lymphoma
Jun 3, 2013
PDF 23.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Approved for Listing on the NASDAQ Capital Market
May 28, 2013
PDF 106.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Presentation of Phase 1 Data for Single-Agent Ublituximab (TG-1101) at the American Society of Clinical Oncology Meeting on June 2, 2013
May 16, 2013
PDF 109.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces First Quarter 2013 Financial Results and Business Update
May 13, 2013
PDF 116.5 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on First Quarter 2013 Financial Results and Business Update
May 10, 2013
PDF 106.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 12th Annual Needham Healthcare Conference
Apr 29, 2013
PDF 107.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at the 25th Annual ROTH Conference
Mar 18, 2013
PDF 14.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results and Business Update
Mar 12, 2013
PDF 119.4 KB Add to Briefcase
Showing 161-180 of 202 Page: 1 ... 5 6 7 8 9 10 11  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase